


1646

IFW



CERTIFICATE OF EXPRESS MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Concise Statement of Relevance of Non-English References, Additional Information, Form PTO-1449 (1 Sheets), and 3 summaries for references are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

Date: 4/4/06 By: [Signature]

Attorney Docket No.: 102530-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Gerd Vallukat et al.
SERIAL NO. : 09/868,967
CUSTOMER NO. : 27387
FILED : June 22, 2001
FOR : Peptides and the AT₁ Receptor and Their Use for Preeclampsia and Malign Hypertension
ART UNIT : 1646
EXAMINER : TBA

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied.
Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance

All references listed on the attached Form PTO-1449 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By 

Bruce S. Londa
Reg. No. 33,531
875 Third Avenue
18th Floor
New York, New York 10022
(212) 808-0700

**LIST OF PATENTS AND PUBLICATIONS
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**
(Form PTO-1449)

Attorney Docket: 102530-4

Serial No.: 09/868,967

Applicant: Gerd Vallukat et al.

Examiner: TBA

Filing Date: June 22, 2001

Group: 1646

U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Date	Name	Class	Sub Class	Filing Date If appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	V. Homuth, et al.; "Characterization of Agonistic Antibodies against the Angiotensin AT ₁ Receptor in Patients with Preeclampsia and HELLP Syndrome"; Kidney Blood Press Res; 1998, Volume 21; page 358; Summary only.
	AB	S. Holzsch et al.; "The Pathophysiological Background of a Sustained Blood Pressure Reduction after Serial Water Immersion"; Kidney Blood Press Res; 1998, Volume 21; page 358; Summary only.
	AC	N. Hubner, et al.; "Elevated Blood Pressure in Congenic Animals Carrying Chromosome 1 Alleles from the Stroke Prone Spontaneously Hypertensive Rat (SHRSP _{HD}); Kidney Blood Press Res; 1998, Volume 21; page 358; Summary only.

EXAMINER:**DATE CONSIDERED:**

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.